期刊
CANCER LETTERS
卷 300, 期 2, 页码 122-133出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2010.09.013
关键词
MUC1; Monoclonal antibody C595; Ovarian cancer; Docetaxel; Combination therapy; Apoptosis
类别
资金
- Henan Health Board China
- Cancer Institute NSW
The purpose of this study was to investigate the in vitro effect of anti-MUC1 monoclonal antibody (MAb) C595 alone and in combination with docetaxel on the growth and survival of different epithelial ovarian cancer (EOC) cell lines MUC1 expression was assessed on EOC cell lines (OVCAR 3 IGROV-1 A2780 CAOV-3 TOV-21G TOV-112D SKOV-3 and OV-90) using immunofluorescence labeling and flow cytometry The effect of MAb C595 alone or in combination with docetaxel on the cell lines was studied by proliferation colony and TUNEL assays Our results indicate that all primary and metastatic EOC cell lines tested were positive to MAb C595 (MUC1) MAb C595 inhibited EOC cell proliferation in a MUC1- and dose-dependent manner low-dose MAb C595 (1/2 of IC(50)) combined with docetaxel greatly improved efficiency of cell killing in EOC cells and Induced apoptosis the additive effect of MAb C595 was further confirmed in colony forming assays and cell death following single or combined treatments was associated with the release of cytochrome c and increased caspase-3 activity These results suggest that MAb C595 used either alone or combined with docetaxel is an attractive strategy for targeting human EOC (C) 2010 Elsevier Ireland Ltd All rights reserved
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据